CClinicalTrials.gg
Sign In
CompletedNCT03444012Updated Aug 7, 2020

ADHERE-S (NIS Brilique)

An observational study in ACS (Acute Coronary Syndrome), sponsored by AstraZeneca. Completed at 9 sites in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-07.

Sponsored by AstraZeneca · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
269
Ages
18 Years and older
Sex
All
01

Study summary

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

02

Conditions studied

  • ACS (Acute Coronary Syndrome)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult ACS patients

Inclusion criteria

  • ≥ 18 years of age
  • diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
  • Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
  • read and signed the Informed Consent Form

Exclusion criteria

Exclusion Criteria:

Any contraindications as per approved SmPC of Brilique

  • Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
269 participants (actual)
Patient registry
No

Interventions

  • Drugticagrelor 90 mg

    persistence and adherence on ticagrelor in ACS patients

05

What researchers measure

Primary outcomes

  1. duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome

    Time frame: 1 year (12 months)

06

Study locations

9 sites
  • CHC Bezanijska Kosa
    Belgrade, Serbia
  • CHC Zemun
    Belgrade, Serbia
  • CHC Zvezdara
    Belgrade, Serbia
  • Clinical Center of Serbia
    Belgrade, Serbia
  • Institute for cardiovascular diseases, Dedinje
    Belgrade, Serbia
  • Medical Military Academy
    Belgrade, Serbia
  • Clinical Center Kragujevac
    Kragujevac, Serbia
  • Clinical Center Nis
    Nis, Serbia
  • Institute for cardiovascular diseases of Vojvodina
    Sremska Kamenica, Serbia
07

References and documents

08

Registry details

Key details

Study ID
NCT03444012
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Mar 5, 2018
Primary completion
Aug 13, 2019
Completion
Aug 13, 2019
Last update
Aug 7, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Coronary Syndrome→

Other studies from this sponsor

AstraZeneca

Start the discussion